BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced on January 13, 2026 that it awarded an inducement grant on January 10, 2026 under its 2025 Inducement Plan to an individual hired in December 2025.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced on January 13, 2026 that it awarded an inducement grant on January 10, 2026 under its 2025 Inducement Plan to an individual hired in December 2025.

The grant comprises non-qualified stock options to purchase 129,090 shares of common stock at an exercise price of $13.19 per share (the Nasdaq closing price on the grant date). The options vest 25% on the first anniversary of the employee’s start date and then in 36 equal monthly installments, subject to continued service. The 2025 Inducement Plan was adopted by the board in October 2025, and the awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Argus Jan 14 session

+4.60% close to close Open Argus

Details

News Market Reaction – BBOT

In the Jan 14 session, BBOT gained 4.60%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard inducement stock option grant of 129,090 shares at an exercise ...

Analysis

This announcement details a standard inducement stock option grant of 129,090 shares at an exercise price of $13.19 under BBOT’s 2025 Inducement Plan, structured to comply with Nasdaq Listing Rule 5635(c)(4). Historically, similar HR or administrative items, such as the prior December 2025 inducement grant, have had less impact than clinical and preclinical RAS/PI3Kα updates. Investors following BBOT may focus more on upcoming trial data and program milestones than on routine equity awards when assessing the company’s trajectory.

Key Figures

Inducement options granted: 129,090 shares Exercise price: $13.19 per share Par value: $0.0001 per share +3 more

Inducement options granted

129,090 shares

Non-qualified stock options under 2025 Inducement Plan

Exercise price

$13.19 per share

Closing price on January 10, 2026 grant date

Par value

$0.0001 per share

BBOT common stock par value

Initial vesting

25% after 1 year

Cliff vesting on first anniversary of start date

Remaining vesting schedule

36 monthly installments

After first anniversary, subject to continued service

Nasdaq rule reference

Rule 5635(c)(4)

Basis for inducement grant exemption

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Clinical data update

   24h Move

   +4.4%

   Preliminary Phase 1 safety and antitumor data across three RAS/PI3Kα programs.

2. Dec 16

   Conference presentation

   24h Move

   -1.3%

   Notice of J.P. Morgan Healthcare Conference presentation and webcast availability.

3. Dec 11

   Inducement grant

   24h Move

   -1.9%

   Stock option inducement grant for a new hire under the 2025 Inducement Plan.

4. Dec 10

   Preclinical data

   24h Move

   +2.8%

   Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.

5. Nov 18

   Investor conferences

   24h Move

   -1.8%

   Participation in multiple December healthcare investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, exercise price, Nasdaq Listing Rule 5635(c)(4), inducement grant

4 terms

non-qualified stock options financial

"The employee received non-qualified stock options to purchase 129,090 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"...with an exercise price of $13.19 per share, the closing price of BBOT’s common stock..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"...as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"...announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan..."

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025.

The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $13.19 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Oncology Therapeutics (BBOT) announce on January 13, 2026?

BBOT announced an inducement grant awarded January 10, 2026 of non-qualified stock options to a new employee hired in December 2025.

How many shares and what exercise price were included in the BBOT inducement grant?

The grant covers options to purchase 129,090 shares with an exercise price of $13.19 per share.

What is the vesting schedule for the BBOT options granted under the 2025 Inducement Plan?

The options vest 25% on the first anniversary of the employee’s start date and then in 36 equal monthly installments thereafter, subject to continued service.

When was BBOT's 2025 Inducement Plan adopted and who approved the awards?

The board adopted the 2025 Inducement Plan in October 2025, and the compensation committee approved the awards as a material inducement under Nasdaq Listing Rule 5635(c)(4).

Does the announced grant affect BBOT shareholders immediately?

The announcement grants options that may dilute shares if exercised in the future, but no immediate share issuance was reported in the announcement.

Why were the awards granted outside BBOT’s stockholder-approved equity plans?

The awards were granted as material inducement grants under the company’s separate 2025 Inducement Plan for a newly hired employee, consistent with Nasdaq Listing Rule 5635(c)(4).